Ultragenyx Pharmaceutical (RARE) Common Equity (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Common Equity of -$236.0 million for Q1 2026, down 263.89% year-over-year from $144.0 million in Q1 2025, and down 195.0% on a QoQ basis from -$80.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Common Equity data on file, last reported at -$236.0 million in Q1 2026.
- Quarterly Common Equity fell 263.89% year-over-year to -$236.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$236.0 million (down 263.89% YoY) and the FY2025 annual result came in at -$80.0 million, down 131.37% from the prior year.
- Common Equity fell to -$236.0 million in Q1 2026 per RARE's latest filing, from -$80.0 million in the prior quarter.
- Across five years, Common Equity topped out at $796.4 million in Q1 2022 and bottomed at -$236.0 million in Q1 2026.
- The 5-year median for Common Equity is $220.5 million (2023), against an average of $242.0 million.
- The widest annual swing landed in 2024, when Common Equity surged 993.61%; it then slumped 263.89% in 2026.
- Tracing RARE's Common Equity over 5 years: stood at $352.0 million in 2022, then fell by 21.88% to $275.0 million in 2023, then decreased by 7.27% to $255.0 million in 2024, then tumbled by 131.37% to -$80.0 million in 2025, then plunged by 195.0% to -$236.0 million in 2026.
- Per Business Quant, the three latest RARE Common Equity figures stand at -$236.0 million (Q1 2026), -$80.0 million (Q4 2025), and $9.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -236.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -236.00 Mn |
| Dec 31, 2025 | -80.00 Mn |
| Sep 30, 2025 | 9.16 Mn |
| Jun 30, 2025 | 151.29 Mn |
| Mar 31, 2025 | 144.00 Mn |
| Dec 31, 2024 | 255.00 Mn |
| Sep 30, 2024 | 346.83 Mn |
| Jun 30, 2024 | 432.42 Mn |
| Mar 31, 2024 | 140.26 Mn |
| Dec 31, 2023 | 275.00 Mn |
| Sep 30, 2023 | 31.71 Mn |
| Jun 30, 2023 | 129.03 Mn |
| Mar 31, 2023 | 220.48 Mn |
| Dec 31, 2022 | 352.00 Mn |
| Sep 30, 2022 | 468.83 Mn |
| Jun 30, 2022 | 678.07 Mn |
| Mar 31, 2022 | 796.42 Mn |
| Dec 31, 2021 | 922.56 Mn |
| Sep 30, 2021 | 933.67 Mn |
| Jun 30, 2021 | 972.17 Mn |
| Mar 31, 2021 | 1.05 Bn |
| Dec 31, 2020 | 1.15 Bn |
| Sep 30, 2020 | 666.19 Mn |
| Jun 30, 2020 | 695.59 Mn |
| Mar 31, 2020 | 609.15 Mn |
| Dec 31, 2019 | 653.76 Mn |
| Sep 30, 2019 | 727.27 Mn |
| Jun 30, 2019 | 819.79 Mn |
| Mar 31, 2019 | 886.73 Mn |
| Dec 31, 2018 | 608.91 Mn |
| Sep 30, 2018 | 662.60 Mn |
| Jun 30, 2018 | 703.97 Mn |
| Mar 31, 2018 | 723.66 Mn |
| Dec 31, 2017 | 383.45 Mn |
| Sep 30, 2017 | 365.56 Mn |
| Jun 30, 2017 | 429.45 Mn |
| Mar 31, 2017 | 488.48 Mn |
| Dec 31, 2016 | 473.97 Mn |
| Sep 30, 2016 | 455.89 Mn |
| Jun 30, 2016 | 443.90 Mn |
| Mar 31, 2016 | 92,000.00 |
| Dec 31, 2015 | 531.09 Mn |
| Sep 30, 2015 | 576.76 Mn |
| Jun 30, 2015 | 319.28 Mn |
| Mar 31, 2015 | 341.12 Mn |
| Dec 31, 2014 | 184.95 Mn |
| Sep 30, 2014 | 199.33 Mn |
| Jun 30, 2014 | 153.08 Mn |
| Mar 31, 2014 | 165.71 Mn |
| Dec 31, 2013 | -74.82 Mn |